FDA approves XARELTO Starter Pack for DVT

Share this content:


FDA has approved the XARELTO Starter Pack™ for deep vein thrombosis or pulmonary embolism.

“Beyond our clinical trials, we continue to pursue innovation that can help support patients,” said Paul Burton, M.D., Ph.D., Janssen's vice president, for medical affairs. “The starter pack will make a difference for patients impacted by blood clots by offering a 30-day supply of the drug in a new convenient package, which may help support patients as they transition from the hospital to out-patient care.”

The medication also is available for once-daily use to reduce the risk of recurrence of DVT or PE following an initial six-month treatment for acute venous thromboembolism, to reduce the risk of stroke or blood clots in those with atrial fibrillation not caused by a heart valve problem. It also can reduce the risk of blood clots in the legs and lungs of people who have just had knee or hip replacement surgery.